rhGGF2 protects against cisplatin-induced neuropathy in the rat

Journal of Neuroscience Research

Volumn 60, Issue 2, 2000, Pages 237-244

  Ter Laak, Mariël P ^a   Hamers, Frank P T ^a,c   Kirk, Cassandra J ^b   Gispen, Willem Hendrik ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b CeNeS Pharmaceuticals plc   (United States)

^c NONE   (Netherlands)

Author keywords

Animal model; Electrophysiology; Morphology; Neuroprotection; Trophic factors

Indexed keywords

CISPLATIN; GROWTH FACTOR; RECOMBINANT HUMAN GLIAL GROWTH FACTOR; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; HISTOPATHOLOGY; MALE; NERVE CONDUCTION; NONHUMAN; PRIORITY JOURNAL; RAT; SATELLITE CELL; SENSORY NEUROPATHY; SPINAL GANGLION;

ANIMALS; BODY WEIGHT; CISPLATIN; GANGLIA, SPINAL; MALE; MICROSCOPY, ELECTRON; NERVE TISSUE PROTEINS; NEURAL CONDUCTION; NEUREGULIN-1; NEUROPROTECTIVE AGENTS; OLIGODENDROGLIA; PERIPHERAL NERVES; PERIPHERAL NERVOUS SYSTEM DISEASES; RATS; RATS, WISTAR; RECOMBINANT PROTEINS;

EID: 0034655960     PISSN: 03604012     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-4547(20000415)60:2<237::AID-JNR13>3.0.CO;2-5     Document Type: Article

References (57)

1. Apfel SC, Arezzo JC, Lipson L, Kessler JA. 1992. Nerve growth factor prevents experimental cisplatin neuropathy. Ann Neurol 31:76-80.
2. Apfel SC, Kessler JA, Adornato BT, Litchy WJ, Sanders C, Rask CA. 1998. Recombinant human nerve growth factor in the treatment of diabetic polyneuropathy. NGF Study Group. Neurology 51:695-702.
3. Barajon I, Bersani M, Quartu M, Del FM, Cavaletti G, Holst JJ, Tredici G. 1996. Neuropeptides and morphological changes in cisplatin-induced dorsal root ganglion neuronopathy. Exp Neurol 138:93-104.
4. Barde YA, Lindsay RM, Monard D, Thoenen H. 1978. New factor released by cultured glioma cells supporting survival and growth of sensory neurones. Nature 274:818
5. Becher R, Schutt P, Osieka R, Schmidt CG. 1980. Peripheral neuropathy and ophthalmologic toxicity after treatment with cis-dichlorodiaminoplatinum II. J Cancer Res Clin Oncol 96:219-222.
6. Berkemeier LR, Winslow JW, Kaplan DR, Nikolics K, Goeddel DV, Rosenthal A. 1991. Neurotrophin-5: a novel neurotrophic factor that activates trk and trkB. Neuron 7:857-866.
7. Blisard KS, Rogers SL, Alexander S, Harrington DA. 1992. Neurotoxic effects of platinum compounds in cultured dorsal root ganglion cells. J Exp Pathol 6:65-74.
8. Boogerd W, ten Bokkel Huinink WW, Dalesio O, Hoppenbrouwers WJ, van der Sande JJ. 1990. Cisplatin induced neuropathy: central, peripheral and autonomic nerve involvement. J Neurooncol 9:255-263.
9. Boyle FM, Wheeler HR, Shenfield GM. 1999. Amelioration of experimental cisplatin and paclitaxel neuropathy with glutamate. J.Neurooncol 41:107-116.
10. Cavaletti G, Minoia C, Schieppati M, Tredici G. 1994. Protective effects of glutathione on cisplatin neurotoxicity in rats. Int J Radiat Oncol Biol Phys 29:771-776.
11. Cavaletti G, Tredici G, Marmiroli P, Petruccioli MG, Barajon I, Fabbrica D. 1992. Morphometric study of the sensory neuron and peripheral nerve changes induced by chronic cisplatin (DDP) administration in rats. Acta Neuropathol Berl 84:364-371.
12. Cece R, Petruccioli MG, Cavaletti G, Barajon I, Tredid G. 1995a. An ultrastructural study of neuronal changes in dorsal root ganglia (DRG) of rats after chronic cisplatin administrations. Histol Histopathol 10:837-845.
13. Cece R, Petruccioli MG, Pizzini G, Cavaletti G, Tredici G. 1995b. Ultrastructural aspects of DRG satellite cell involvement in experimental cisplatin neuronopathy. J Submicrosc Cytol Pathol 27:417-425.
14. Cliffer KD, Siuciak JA, Carson SR, Radley HE, Park JS, Lewis DR, Zlotchenko E, Nguyen T, Garcia K, Tonra JR, Stambler N, Cedarbaum JM, Bodine SC, Lindsay RM, DiStefano PS. 1998. Physiological characterization of Taxol-induced large-fiber sensory neuropathy in the rat. Ann Neurol 43:46-55.
15. Corda Y, Anin MF, Leng M, Job D. 1992. RNA polymerases react differently at d(ApG) and d(GpG) adducts in DNA modified by cis-diamminedichloroplatinum(II). Biochemistry 31:1904-1908.
16. de Koning P, Neijt JP, Jennekens FG, Gispen WH. 1987a. Evaluation of cis-diamminedichloroplatinum (II) (cisplatin) neurotoxicity in rats. Toxicol Appl Pharmacol 89:81-87.
17. de Koning P, Neijt JP, Jennekens FG, Gispen WH. 1987b. Org.2766 protects from cisplatin-induced neurotoxicity in rats. Exp Neurol 97: 746-750.
18. Falls DL, Rosen KM, Corfas G, Lane WS, Fischbach GD. 1993. ARIA, a protein that stimulates acetylcholine receptor synthesis, is a member of the neu ligand family. Cell 72:801-815.
19. Gao WQ, Dybdal N, Shinsky N, Murnane A, Schmelzer C, Siegel M, Keller G, Hefti F, Phillips HS, Winslow JW. 1995. Neurotrophin-3 reverses experimental cisplatin-induced peripheral sensory neuropathy. Ann Nenrol 38:30-37.
20. Gerritsen van der Hoop R, de Koning P, Boven E, Neijt JP, Jennekens FG, Gispen WH. 1988. Efficacy of the neuropeptide ORG.2766 in the prevention and treatment of cisplatin-induced neurotoxicity in rats. Eur J Cancer Clin Oncol 24:637-642.
21. Gerritsen van der Hoop R, Hamers FP, Neijt JP, Veldman H, Gispen WH, Jennekens FG. 1994. Protection against cisplatin induced neurotoxicity by ORG 2766: histological and electrophysiological evidence. J Neurol Sci 126:109-115.
22. Gerritsen van der Hoop R, Van der Burg ME, ten Bokkel Huinink WW, Van Houwelingen C., Neijt JP. 1990a. Incidence of neuropathy in 395 patients with ovarian cancer treated with or without cisplatin. Cancer 66:1697-1702.
23. Gerritsen van der Hoop R, Vecht CJ, Van der Burg MEL, Elderson A, Boogerd W, Heimans JJ, Vries EP, Van Houwelingen JC, Jennekens FGI, Gispen WH, Neijt JP. 1990b. Prevention of cisplatin neurotoxicity with an ACTH(4-9) analogue in patients with ovarian cancer. N Engl J Med 322:89-94.
24. Gill JS, Windebank AJ. 1998. Cisplatin-induced apoptosis in rat dorsal root ganglion neurons is associated with attempted entry into the cell cycle. J Clin Invest 101:2842-2850.
25. Goodearl AD, Davis JB, Mistry K, Minghetti L, Otsu M, Waterfield MD, Stroobant P. 1993. Purification of multiple forms of glial growth factor. J Biol Chem 268:18095-18102.
26. Hallbook F, Ibanez CF, Persson H. 1991. Evolutionary studies of the nerve growth factor family reveal a novel member abundantly expressed in Xenopus ovary. Neuron 6:845-858.
27. Hamers FP, Pette C, Bravenboer B, Vecht CJ, Neijt JP, Gispen WH. 1993a. Cisplatin-induced neuropathy in mature rats: effects of the melanocortin-derived peptide ORG 2766. Cancer Chemother Pharmacol 32:162-166.
28. Hamers FP, Pette C, Neijt JP, Gispen WH. 1993b. The ACTH(4-9) analog, ORG 2766, prevents taxol-induced neuropathy in rats. Eur J Pharmacol 233:177-178.
29. Hamers FP, Plantinga LC, Verhaagen J, Neijt JP, Gispen WH. 1996. Upregulation of B50/GAP-43 protein mRNA in rat dorsal root ganglia during cisplatin intoxication. J Neurosci Res 44:142-148.
30. Hamers FPT, Gispen WH, Neijt JP. 1991. Neurotoxic side-effects of cisplatin. Eur J Cancer 27:372-376.
31. Hefti F. 1994. Neurotrophic factor therapy for nervous system degenerative diseases. J Neurobiol 25:1418-1435.
32. Helgren ME, Cliffer KD, Torrento K, Cavnor C, Curtis R, DiStefano PS, Wiegand SJ, Lindsay RM. 1997. Neurotrophin-3 administration attenuates deficits of pyridoxine-induced large-fiber sensory neuropathy. J Neurosci 17:372-382.
33. Holmes WE, Sliwkowski MX, Akita RW, Henzel WJ, Lee J, Park JW, Yansura D, Abadi N, Raab H, Lewis GD. 1992. Identification of heregulin, a specific activator of p185erbB2. Science 256:1205-1210.
34. Huang H, Zhu L, Reid BR, Drobny GP, Hopkins PB. 1995. Solution structure of a cisplatin-induced DNA interstrand cross-link. Science 270: 1842-1845.
35. Klein R, Silos SI, Smeyne RJ, Lira SA, Brambilla R, Bryant S, Zhang L, Snider WD, Barbacid M. 1994. Disruption of the neurotrophin-3 receptor gene trkC eliminates la muscle afferents and results in abnormal movements. Nature 368:249-251.
36. Lemke GE, Brockes JP. 1984. Identification and purification of glial growth factor. J Neurosci 4:75-83.
37. Lewin GR, Ritter AM, Mendell LM. 1993. Nerve growth factor-induced hyperalgesia in the neonatal and adult rat. J Neurosci 13:2136-2148.
38. Mahanthappa NK, Anton ES, Matthew WD. 1996. Glial growth factor 2, a soluble neuregulin, directly increases Schwann cell motility and indirectly promotes neurite outgrowth. J Neurosci 16:4673-4683.
39. Marchionni MA, Goodearl AD, Chen MS, Bermingham MO, Kirk C, Hendricks M, Danehy F, Misumi D, Sudhalter J, Kobayashi K, Wroblewski D, Lynch C, Baldassare M, Hiles I, Davis JB, Hsuan JJ, Totty NF, Otsi M. McBurney RN, Waterfield MD, Stroobant P, Gwynne D. 1993. Glial growth factors are alternatively spliced erbB2 ligands expressed in the nervous system. Nature 362:312-318.
40. Marchionni MA, Kirk CJ, Isaacs IJ, Hoban CJ, Mahanthappa NK, Anton ES, Chen C, Wason F, Lawson D, Hamers FP, Canoll PD, Reynolds R, Cannella B, Meun D, Holt WF, Matthew WD, Chen LE, Gispen WH, Raine CS, Salzer JL, Gwynne DI. 1996. Neuregulins as potential drugs for neurological disorders. Cold Spring Harbor Symp Quant Biol 61: 459-472.
41. Mollman JE. 1990. Cisplatin neurotoxicity. N Engl J Med 322:126-127.
42. Mollman JE, Glover DJ, Hogan WM, Furman RE. 1988. Cisplatin neuropathy. Risk factors, prognosis, and protection by WR-2721. Cancer 61:2192-2195.
43. Müller LJ, Gerritsen van der Hoop R, Moorer van Delft M, Gispen WH, Roubos EW. 1990. Morphological and electrophysiological study of the effects of cisplatin and ORG2766 on rat spinal ganglion neurons. Cancer Res 50 2437-2444.
44. Ozols RF, Ostchega Y, Myers CE, Young RC. 1985. High-dose cisplatin in hypertonic saline in refractory ovarian cancer. J Clin Oncol 3:1246-1250.
45. Pascoe JM, Roberts JJ. 1974. Interactions between mammalian cell DNA and inorganic platinum compounds. I. DNA interstrand cross-linking and cytotoxic properties of platinum(II) compounds. Biochem Pharmacol 23:1359-1365.
46. Pinto AL, Lippard SJ. 1985. Binding of the antitumor drug cis-diamminedichloroplatinum(II) (cisplatin) to DNA. Biochim Biophys Acta 780:167-180.
47. Roelofs RI, Hrushesky W, Rogin J, Rosenberg L. 1984. Peripheral sensory neuropathy and cisplatin chemotherapy. Neurology 34:934-938.
48. Stacchiotti A, Rezzani R, Rodella L, Ventura RG. 1995. Lysosomal changes in rat spinal ganglid neurons after prolonged treatment with cisplatin. Acta Anat (Basel) 153:236-242.
49. Terheggen PM, Gerritsen van der Hoop R, Floot BG, Gispen WH. 1989. Cellular distribution of cis-diamminedichloroplatinum(II)-DNA binding in rat dorsal root spinal ganglia: effect of the neuro-protecting peptide ORG.2766. Toxicol Appl Pharmacol 99:334-343.
50. Thompson SW, Davis LE, Kornfeld M, Hilgers RD, Standefer JC. 1984. Cisplatin neuropathy. Clinical, electrophysiologic, morphologic, and toxicologic studies. Cancer 54:1269-1275.
51. Tomiwa K, Nolan C, Cavanagh JB. 1986. The effects of cisplatin on rat spinal ganglia: a study by light and electron microscopy and by morphometry. Acta Neuropathol Berl 69:295-308.
52. Trachtenberg JT, Thompson WJ. 1996. Schwann cell apoptosis at developing neuromuscular junctions is regulated by glial growth factor. Nature 379:174-177.
53. Tredici G, Braga M, Nicolini G, Miloso M, Marmiroli P, Schenone A, Nobbio L, Frattola L, Cavaletti G. 1999. Effects of recombinant human nerve growth factor on cisplatin neurotoxicity in rats. Exp Neurol 159:552-558.
54. Van Gerven JM, Hovestadt A, Moll JW, Rodenburg CJ, Splinter TA, Van Oosterom AT, Keizer L, Drogendijk TE, Groenhout CM, Vecht CJ, Neijt JP. 1994. The effects of an ACTH(4-9) analogue on development of cisplatin neuropathy in testicular cancer: a randomized trial. J Neurol 241:432-435.
55. Verdi JM, Groves AK, Farinas I, Jones K, Marchionni MA, Reichardt LF, Anderson DJ. 1996. A reciprocal cell-cell interaction mediated by NT-3 and neuregulins controls the early survival and development of sympathetic neuroblasts. Neuron 16:515-527.
56. Walsh TJ, Clark AW, Parhad IM, Green WR. 1982. Neurotoxic effects of cisplatin therapy. Arch Neurol 39:719-720.
57. Wen D, Peles E, Cupples R, Suggs SV, Bacus SS, Luo Y, Trail G, Hu S, Silbiger SM, Levy RB, Koski RA, Lu HS, Yarden Y. 1992. Neu differentiation factor: a transmembrane glycoprotein containing an EGF domain and an immunoglobulin homology unit. Cell 69:559-572.